These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 17445122

  • 1. Inhibitors, what is the risk of treatment intensity?
    Collins PW.
    J Thromb Haemost; 2007 Jul; 5(7):1380-2. PubMed ID: 17445122
    [No Abstract] [Full Text] [Related]

  • 2. Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
    Hermans C, Astermark J, De Moerloose P.
    J Thromb Haemost; 2012 Oct; 10(10):2194-6. PubMed ID: 22846047
    [No Abstract] [Full Text] [Related]

  • 3. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
    Gouw SC, van den Berg HM, le Cessie S, van der Bom JG.
    J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
    [Abstract] [Full Text] [Related]

  • 4. Suggestions for the management of factor VIII inhibitors.
    Rubinger M, Rivard GE, Teitel J, Walker H, Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada.
    Haemophilia; 2000 Jul; 6 Suppl 1():52-9. PubMed ID: 10982269
    [No Abstract] [Full Text] [Related]

  • 5. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
    Iioka F, Shimomura D, Nakamura F, Ohno H, Yada K, Nogami K, Shima M.
    Haemophilia; 2014 Nov; 20(6):e402-4. PubMed ID: 25354772
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
    Roberts HR.
    Vox Sang; 1999 Nov; 77 Suppl 1():38-41. PubMed ID: 10529686
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Complications of hemophilia A treatment: factor VIII inhibitors.
    Kasper CK.
    Ann N Y Acad Sci; 1991 Nov; 614():97-105. PubMed ID: 1902643
    [No Abstract] [Full Text] [Related]

  • 10. The management of hemophilia patients with inhibitors.
    Nilsson IM.
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract] [Full Text] [Related]

  • 11. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A, Roisenberg I.
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract] [Full Text] [Related]

  • 12. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
    Wu RH, Wei QQ.
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
    [No Abstract] [Full Text] [Related]

  • 13. Hemophilia treatment. Side effects during immune tolerance induction.
    Brackmann HH, Schwaab R, Effenberger W, Hess L, Hanfland P, Oldenburg J.
    Haematologica; 2000 Oct; 85(10 Suppl):75-7. PubMed ID: 11187878
    [No Abstract] [Full Text] [Related]

  • 14. Assessing the risk of inhibitor formation with different factor VIII products.
    Mannucci PM.
    Blood; 2006 May 01; 107(9):3809-10; author reply 3810. PubMed ID: 16627765
    [No Abstract] [Full Text] [Related]

  • 15. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
    Clere AS, Diaz I, Lebreton A, Lavigne-Lissalde G, Schved JF, Biron-Andreani C.
    Haemophilia; 2014 Nov 01; 20(6):e406-8. PubMed ID: 25311419
    [No Abstract] [Full Text] [Related]

  • 16. Inhibitors in haemophilia: a primer.
    DiMichele DM.
    Haemophilia; 2000 Jul 01; 6 Suppl 1():38-40. PubMed ID: 10982266
    [No Abstract] [Full Text] [Related]

  • 17. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients.
    Roussel-Robert V, Torchet MF, Legrand F, Rothschild C, Stieltjes N.
    J Thromb Haemost; 2003 Nov 01; 1(11):2450-1. PubMed ID: 14629482
    [No Abstract] [Full Text] [Related]

  • 18. Anti-factor VIII antibodies (Inhibitors) in hemophilia A: in dire need of basic and therapeutic research.
    Kaveri SV.
    Clin Rev Allergy Immunol; 2009 Oct 01; 37(2):55-7. PubMed ID: 19153680
    [No Abstract] [Full Text] [Related]

  • 19. Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.
    Scott DW, Pratt KP.
    Front Immunol; 2019 Oct 01; 10():3078. PubMed ID: 32010137
    [Abstract] [Full Text] [Related]

  • 20. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D, Rodgers GM.
    Eur J Haematol; 2015 Apr 01; 94(4):283. PubMed ID: 25800968
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.